# Phase 3 carcinoma trials recruiting: 329 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 329 trials in phase 3 for carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 carcinoma trials: 329 rows for $16.45, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 8 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 329
- Recruiting or not yet: 329
- Read on: November 19, 2026

## Trials

The 25 newest of 329, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947121 | A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer... | GlaxoSmithKline | Phase 3 | Not yet recruiting | Lung Neoplasm | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947121) |
| November 17, 2026 | NCT07943325 | Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer | Goethe University | Phase 3 | Not yet recruiting | Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943325) |
| November 9, 2026 | NCT07926048 | A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926048) |
| November 9, 2026 | NCT07925021 | A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Recruiting | Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma | 424 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925021) |
| November 9, 2026 | NCT07924111 | A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 585 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924111) |
| November 2, 2026 | NCT07908745 | Reduced-Dose vs Standard-Dose Thoracic Radiotherapy After Induction Chemoimmunotherapy in Older or Frail Stage III NSCLC | Ruijin Hospital | Phase 3 | Not yet recruiting | Non-Small-Cell Lung Cancer | 276 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908745) |
| November 2, 2026 | NCT07908732 | Risk-Adapted Segmental Esophagus-Sparing Radiotherapy for Definitive Non-Small Cell Lung Cancer | Ruijin Hospital | Phase 3 | Not yet recruiting | Non-Small Cell Lung Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908732) |
| November 2, 2026 | NCT07908537 | A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004) | Merck Sharp & Dohme LLC | Phase 3 | Not yet recruiting | Small Cell Lung Cancer | 564 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908537) |
| October 26, 2026 | NCT07896005 | A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Not yet recruiting | Non Small Cell Lung Cancer | 436 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896005) |
| October 26, 2026 | NCT07895732 | Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma | University Health Network, Toronto | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895732) |
| October 26, 2026 | NCT07895238 | A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC | West China Hospital | Phase 3 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 1,088 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895238) |
| October 16, 2026 | NCT07877584 | PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% | German Cancer Research Center | Phase 3 | Not yet recruiting | Non-Small Cell Lung Cancer | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877584) |
| October 5, 2026 | NCT07859215 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line... | Genmab | Phase 3 | Not yet recruiting | Ovarian Cancer | 602 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859215) |
| October 1, 2026 | NCT07851025 | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced... | AstraZeneca | Phase 3 | Recruiting | Epithelial Ovarian Cancer | 950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851025) |
| September 23, 2026 | NCT07836530 | Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma | BeOne Medicines | Phase 3 | Recruiting | Hepatocellular Carcinoma, Liver Cancer | 492 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836530) |
| September 22, 2026 | NCT07833839 | ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 | Not yet recruiting | Neuroendocrine Carcinomas (NEC) | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833839) |
| September 16, 2026 | NCT07823348 | JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer | Shanghai Junshi Bioscience Co., Ltd. | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823348) |
| September 16, 2026 | NCT07822542 | A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as... | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Carcinoma, Non-Small-Cell Lung | 448 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822542) |
| September 16, 2026 | NCT07821684 | A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR... | AbbVie | Phase 3 | Not yet recruiting | Non-Squamous Non-Small Cell Lung Cancer | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821684) |
| September 14, 2026 | NCT07816666 | Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer | AstraZeneca | Phase 3 | Recruiting | Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer... | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816666) |
| September 11, 2026 | NCT07816380 | A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic... | Guangzhou JOYO Pharma Co., Ltd | Phase 3 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816380) |
| September 10, 2026 | NCT07813572 | ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 | Recruiting | Hepatocellular Carcinoma | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813572) |
| September 10, 2026 | NCT07811271 | Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal... | BeOne Medicines | Phase 3 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811271) |
| September 9, 2026 | NCT07809256 | A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in... | EuroCityClinic LLC | Phase 3 | Recruiting | NSCLC (Non-small Cell Lung Cancer)R | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809256) |
| September 3, 2026 | NCT07802821 | A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih... | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Extensive-stage Small Cell Lung Cancer | 556 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802821) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sun Yat-sen University | 30 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 12 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 10 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 7 |
| Fudan University | 6 |
| National Cancer Institute (NCI) | 6 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 6 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 6 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 5 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 5 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 5 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 4 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 4 |
| Tianjin Medical University Cancer Institute and Hospital | 4 |
| [Suzhou Suncadia Biopharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/suzhou-suncadia-biopharmaceuticals-co-ltd) | 4 |
| [Suzhou Zelgen Biopharmaceuticals Co.,Ltd](https://specstream.ai/data/clinical-trials/company/suzhou-zelgen-biopharmaceuticals-co-ltd) | 4 |
| Henan Cancer Hospital | 3 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 3 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 3 |
| ETOP IBCSG Partners Foundation | 3 |
| Eye & ENT Hospital of Fudan University | 3 |
| NRG Oncology | 3 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 3 |
| [Hansoh BioMedical R&D Company](https://specstream.ai/data/clinical-trials/company/hansoh-biomedical-r-and-d-company) | 3 |
| [Changchun GeneScience Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/changchun-genescience-pharmaceutical-co-ltd) | 3 |

## By country

| Country | Trials |
| --- | --- |
| China | 204 |
| United States | 87 |
| Spain | 66 |
| France | 63 |
| Italy | 62 |
| Canada | 60 |
| Japan | 58 |
| Germany | 57 |
| South Korea | 56 |
| United Kingdom | 56 |
| Australia | 54 |
| Poland | 53 |
| Taiwan | 49 |
| Brazil | 47 |
| Turkey (Türkiye) | 41 |
| Netherlands | 40 |
| Belgium | 39 |
| Greece | 39 |
| Argentina | 32 |
| Romania | 32 |
| Austria | 31 |
| Hungary | 29 |
| India | 27 |
| Czechia | 27 |
| Chile | 26 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B industrial and machine companies in the United States](https://specstream.ai/data/businesses/b2b-industrial-and-machine-companies/united-states)
- [International fusion restaurants in the United States](https://specstream.ai/data/businesses/international-fusion-restaurants/united-states)
- [Vegan restaurants in the United States](https://specstream.ai/data/businesses/vegan-restaurants/united-states)
- [Fingerprinting services in the United States](https://specstream.ai/data/businesses/fingerprinting-services/united-states)
- [Scientific laboratories in the United States](https://specstream.ai/data/businesses/scientific-laboratories/united-states)
- [Cosmetic products manufacturers in the United States](https://specstream.ai/data/businesses/cosmetic-products-manufacturers/united-states)
